Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 7466.74 | 653 / 653 | 100% | 49.09 | 602 / 605 |
kidney | 100% | 8553.56 | 89 / 89 | 96% | 68.91 | 864 / 901 |
prostate | 100% | 5442.25 | 244 / 245 | 96% | 30.07 | 480 / 502 |
lung | 100% | 6065.51 | 577 / 578 | 93% | 28.28 | 1074 / 1155 |
breast | 100% | 5518.54 | 459 / 459 | 91% | 17.88 | 1012 / 1118 |
liver | 97% | 3943.39 | 219 / 226 | 91% | 17.59 | 370 / 406 |
uterus | 100% | 8959.02 | 170 / 170 | 84% | 32.28 | 384 / 459 |
esophagus | 94% | 3941.20 | 1365 / 1445 | 86% | 37.98 | 157 / 183 |
brain | 79% | 1790.13 | 2076 / 2642 | 98% | 28.78 | 692 / 705 |
ovary | 100% | 11816.67 | 180 / 180 | 72% | 13.45 | 309 / 430 |
bladder | 100% | 5477.52 | 21 / 21 | 67% | 16.54 | 340 / 504 |
adrenal gland | 98% | 3293.09 | 252 / 258 | 69% | 12.22 | 159 / 230 |
skin | 72% | 9845.40 | 1308 / 1809 | 94% | 27.41 | 444 / 472 |
stomach | 92% | 2914.23 | 330 / 359 | 72% | 16.08 | 207 / 286 |
intestine | 98% | 4793.75 | 943 / 966 | 54% | 9.26 | 283 / 527 |
pancreas | 8% | 132.58 | 27 / 328 | 94% | 22.87 | 167 / 178 |
adipose | 100% | 7665.54 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 7279.06 | 241 / 241 | 0% | 0 | 0 / 0 |
muscle | 97% | 4555.83 | 782 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 42.35 | 43 / 45 |
blood vessel | 85% | 2647.54 | 1138 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 22.40 | 24 / 29 |
eye | 0% | 0 | 0 / 0 | 79% | 16.33 | 63 / 80 |
heart | 48% | 934.98 | 411 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 20% | 494.18 | 188 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0048839 | Biological process | inner ear development |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0070306 | Biological process | lens fiber cell differentiation |
GO_0030219 | Biological process | megakaryocyte differentiation |
GO_0032330 | Biological process | regulation of chondrocyte differentiation |
GO_0140467 | Biological process | integrated stress response signaling |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAF |
Protein name | Transcription factor Maf Transcription factor Maf (Proto-oncogene c-Maf) (V-maf musculoaponeurotic fibrosarcoma oncogene homolog) |
Synonyms | |
Description | FUNCTION: Acts as a transcriptional activator or repressor. Involved in embryonic lens fiber cell development. Recruits the transcriptional coactivators CREBBP and/or EP300 to crystallin promoters leading to up-regulation of crystallin gene during lens fiber cell differentiation. Activates the expression of IL4 in T helper 2 (Th2) cells. Increases T-cell susceptibility to apoptosis by interacting with MYB and decreasing BCL2 expression. Together with PAX6, transactivates strongly the glucagon gene promoter through the G1 element. Activates transcription of the CD13 proximal promoter in endothelial cells. Represses transcription of the CD13 promoter in early stages of myelopoiesis by affecting the ETS1 and MYB cooperative interaction. Involved in the initial chondrocyte terminal differentiation and the disappearance of hypertrophic chondrocytes during endochondral bone development. Binds to the sequence 5'-[GT]G[GC]N[GT]NCTCAGNN-3' in the L7 promoter. Binds to the T-MARE (Maf response element) sites of lens-specific alpha- and beta-crystallin gene promoters. Binds element G1 on the glucagon promoter. Binds an AT-rich region adjacent to the TGC motif (atypical Maf response element) in the CD13 proximal promoter in endothelial cells (By similarity). When overexpressed, represses anti-oxidant response element (ARE)-mediated transcription. Involved either as an oncogene or as a tumor suppressor, depending on the cell context. Binds to the ARE sites of detoxifying enzyme gene promoters. . |
Accessions | H3BP11 O75444 ENST00000569649.1 ENST00000326043.5 [O75444-1] ENST00000393350.1 [O75444-2] Q71A33 |